These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17701579)

  • 61. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment.
    Kitahara H; Maruyama D; Maeshima AM; Makita S; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Terauchi T; Kurihara H; Taniguchi H; Komatsu N; Tobinai K
    Ann Hematol; 2017 Mar; 96(3):411-420. PubMed ID: 27928587
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
    Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
    Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
    Smith SD; Bolwell BJ; Rybicki LA; Brown S; Dean R; Kalaycio M; Sobecks R; Andresen S; Hsi ED; Pohlman B; Sweetenham JW
    Bone Marrow Transplant; 2007 Aug; 40(3):239-43. PubMed ID: 17530000
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Majolino I; Pearce R; Taghipour G; Goldstone AH
    J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management.
    Zain JM; Hanona P
    Am J Hematol; 2021 Aug; 96(8):1027-1046. PubMed ID: 34111312
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Current management of peripheral T-cell lymphomas.
    Gooptu M; Rhoades R; Pro B
    Cancer Treat Res; 2015; 165():289-303. PubMed ID: 25655615
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.
    Goldberg JD; Chou JF; Horwitz S; Teruya-Feldstein J; Barker JN; Boulad F; Castro-Malaspina H; Giralt S; Jakubowski AA; Koehne G; van den Brink MRM; Young JW; Zhang Z; Papadopoulos EB; Perales MA
    Leuk Lymphoma; 2012 Jun; 53(6):1124-1129. PubMed ID: 22136377
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The aggressive peripheral T-cell lymphomas: 2015.
    Armitage JO
    Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
    Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C
    Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.
    Jantunen E; Wiklund T; Juvonen E; Putkonen M; Lehtinen T; Kuittinen O; Franssila K; Söderström KO; Leppä S; Elonen E; Remes K; Nousiainen T
    Bone Marrow Transplant; 2004 Feb; 33(4):405-10. PubMed ID: 14676776
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases.
    Picleanu AM; Novelli S; Monter A; Garcia-Cadenas I; Caballero AC; Martino R; Esquirol A; Briones J; Sierra J
    Ann Hematol; 2017 May; 96(5):787-796. PubMed ID: 28168350
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of Peripheral T-Cell Lymphoma in Community Settings.
    Feldman T; Farber CM; Choi K; Faria C; Goy A; Connors J; Paramanathan D; Kaur S; Schultz E; McGuire M; Goldberg SL
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):354-361. PubMed ID: 28622960
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
    Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
    Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
    Vranovsky A; Ladicka M; Lakota J
    Neoplasma; 2008; 55(2):107-12. PubMed ID: 18652043
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
    Gleeson M; Peckitt C; Cunningham D; Gibb A; Hawkes EA; Back M; Yasar B; Foley K; Lee R; Dash J; Johnson H; O'Hara C; Wotherspoon A; Attygalle A; Menasce L; Shenjere P; Potter M; Ethell ME; Dearden C; Radford J; Chau I; Linton K
    Leuk Lymphoma; 2018 Jul; 59(7):1586-1595. PubMed ID: 29119842
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
    Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
    Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Peripheral T-cell lymphoma: diagnosis and treatment].
    Reimer P; Hentrich M
    Dtsch Med Wochenschr; 2006 Mar; 131(13):685-90. PubMed ID: 16555177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.